Life after treatment for follicular lymphoma brings long-term physical and emotional challenges, including immune system ...
Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.
Pharmaceutical Technology on MSN6d
EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapyThe European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...
Pharmaceutical Technology on MSN1d
China conditionally approves Hutchmed’s Tazverik for follicular lymphomaChina’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik ...
Wojciech Jurczak, MD, PhD, ​​discusses nemtabrutinib and its development for the treatment of follicular lymphoma.
Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.
Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.
The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback